Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-53.86M | $-1.03 |
| 2024 | $0.00 | $-25.49M | $-0.76 |
| 2023 | $0.00 | $-21.25M | $-0.88 |
| 2022 | $0.00 | $-18.49M | $-0.96 |
| 2021 | $0.00 | $-18.03M | $-1.63 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-0.26 per share
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.23 vs $-0.25beat
- Tue, May 12$-0.23 vs $-0.22miss
- Thu, Mar 12$-0.37 vs $-0.16miss
- Tue, Nov 4$-0.19 vs $-0.23beat
- Tue, Aug 12$-0.26 vs $-0.21miss
- Tue, May 6$-0.21 vs $-0.19miss
Estimates and results for EPRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
EPRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (3)
- Newsglobenewswire.com·2d ago·Negative
…ed Serious Adverse Events (“SAEs”) VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity,…
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
View source ↗ - Newszacks.com·5d ago·Neutral
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗